VALN vs PFE

For growth investors, Valneva SE (VALN) is the stronger pick with 10.

3% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Pfizer Inc. (PFE) offers the better valuation at 19. 5x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Valneva SE (VALN) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Pfizer Inc.

(PFE) delivered a total return of -13. 3%, compared to -81. 2% for Valneva SE (VALN). Over 10 years, the gap is even starker: PFE returned +29. 6% versus VALN's -78. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 54β versus Valneva SE's 0. 99β — meaning VALN is approximately 81% more volatile than PFE relative to the S&P 500. On balance sheet safety, Pfizer Inc. (PFE) carries a lower debt/equity ratio of 78% versus 119% for Valneva SE — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Valneva SE (VALN) is pulling ahead at 10.

3% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Valneva SE grew EPS 88. 4% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, PFE leads at -14. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pfizer Inc.

(PFE) is the more profitable company, earning 12. 4% net margin versus -7. 2% for Valneva SE — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus 7. 9% for VALN. At the gross margin level — before operating expenses — PFE leads at 70. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for VALN: 97.

8% to $11. 00.

In this comparison, PFE (6.

5% yield) pays a dividend. VALN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 6. 5% yield). Both have compounded well over 10 years (PFE: +29. 6%, VALN: -78. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VALN is a small-cap quality compounder stock; PFE is a mid-cap income-oriented stock. PFE pays a dividend while VALN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.